This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2023)
|
HEC88473 is an experimental dual GLP-1 and fibroblast growth factor 21 (FGF21) receptor agonist. It is developed by the Chinese company HEC Pharm for diabetes and non-alcoholic steatohepatitis.[1][2]
![]() | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |